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EXPLORING PROMOTER SILENCING AND RE-EXPRESSION OF 
SH3GL2/ENDOPHILIN A1 IN UROTHELIAL CANCER 




Bladder cancer (BC) is highly prevalent. It presents as either non-muscle invasive 
or muscle-invasive disease. The prognosis of muscle invasive disease is poor, with a 5-
year survival rate of less than 50%. Treatment approaches for both types of BC have not 
advanced much in the last few years and new therapies are needed to overcome the large 
burden of BC. Recently, a large effort has been undertaken to classify BC into molecular 
subtypes. These analyses have revealed significant alterations in epigenetic modifiers in 
BC. A previous study from our group revealed that SH3GL2, a negative regulator of 
receptor tyrosine kinase (RTK) signaling, was lost with high frequency in BC, leading to 
increased growth of tumor cells in-vitro and in-vivo. Conversely, forced expression of 
SH3GL2 in BC cell lines attenuated oncogenic behaviors including growth and migration. 
In addition to genomic deletion, SH3GL2 is subject to methylation-induced silencing, a 
key epigenetic mechanism.  
OBJECTIVE: 
Epigenetic mechanisms of gene regulation are known to be perturbed in BC. The 
objectives of this study were to investigate methylation of the SH3GL2 promoter and to 
test whether agents that promote Deoxyribonucleic acid (DNA) demethylation could be 




Methylation of a specific CpG island in the SH3GL2 promoter was analyzed using 
methylation-specific Polymerase Chain Reaction (PCR) in a panel of BC cell lines with 
known SH3GL2 messenger Ribonucleic Acid (mRNA) status. Selected BC cell lines were 
treated with a variety of demethylating agents at different doses and for different times to 
evoke the re-expression of silenced SH3GL2. Demethylation inhibitors were combined 
with the histone deacetylase inhibitor, trichostatin A (TSA), to determine whether further 
re-expression could be achieved. 
RESULTS: 
The SH3GL2 promoter displayed differing extents of promoter methylation among 
cell lines examined. In RT4 cells, the only cell line with detectable expression of SH3GL2 
mRNA and protein, the promoter was completely unmethylated. In contrast, T24 and 253J 
cells displayed significant promoter methylation with little to no SH3GL2 mRNA 
expressed, consistent with methylation-induced silencing. Treatment of T24 and 253J with 
5-Aza-2’-deoxycytidine (5-Aza-dC, 20 µM), a DNA methyltransferase (DNMT) inhibitor 
increased gene expression but this was not dose- or time-dependent. Two additional DNMT 
inhibitors, Zebularine and RG-108 were also tested. A much higher dosage of Zebularine 
was required to trigger activation (500 µM) while RG-108 was unable to trigger gene 
reactivation at all. Combination treatment with 5-Aza-dC and TSA further increased 
SH3GL2 expression compared to either agent alone. These results suggest that DNA 
methyltransferase inhibition is an effective treatment to re-express SH3GL2 in cells with 




The present study shows silencing of SH3GL2 in a variety of BC cell lines as a 
consequence of DNA promoter hypermethylation. Treatment with demethylating agents 
was able to increase gene expression. Based on prior findings showing attenuation of tumor 
cell growth and migration with forced expression of SH3GL2, DNA methyltransferase 
inhibition represents an effective strategy to re-express SH3GL2 in BC and normalize 
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Bladder cancer (BC) is a highly prevalent cancer with over 70,000 new cases 
diagnosed last year (Siegel et al., 2017). While the majority of cases diagnosed are non-
muscle invasive bladder cancer (NMIBC) and are treated with a transurethral bladder 
resection, they commonly recur (Knowles, 2006). Muscle-invasive BC (MIBC) has a much 
poorer prognosis with a five-year survival rate of less than 50% (Knowles & Hurst, 2015). 
For MIBC, the current standard of care involves radical cystectomy as well as 
chemotherapy. Treatment approaches for both types of BC have not advanced much in the 
last number of years and new therapies are needed to overcome the large burden of BC. 
Recently, there has been a significant effort to identify particular markers that might help 
determine which treatment would be most appropriate for a given patient, as well as those 
unlikely to be beneficial, to ensure optimal treatment. New biomarkers are needed to assess 
whether patients will respond to specific treatments. 
Molecular mechanisms of BC 
BC originates from the urothelium of the bladder along two distinct pathways, 
which gives rise to either papillary NMIBC or non-papillary MIBC (Sanli et al., 2017). 
NMIBC has two common alterations: (i) a loss of heterozygosity (LOH) of chromosome 9 
(Chow et al., 2000; Obermann et al., 2003) and (ii) activating mutations in the Fibroblast 
Growth Factor Receptor 3 gene (FGFR3) (Cappellen et al., 1999). With respect to the first 
common alteration, the LOH of chromosome 9 is found in greater than 50% of bladder 
tumors (Cairns et al., 1993). Chromosome 9, especially region 9p21, is a known location 
of many tumor suppressor genes, including CDKN2A/ARF which encodes two proteins, 
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p16 and p14ARF (Knowles, 2006). Both p16 and p14ARF are key cell cycle regulators. P16 
is a negative regulator of Retinoblastoma (RB) activation, which allows continuous 
activation of Rb, enabling cells to continuously move through the cell cycle unencumbered 
(Benedict et al., 1999). P14ARF is also a negative regulator of another key cell cycle protein, 
p53 (Knowles, 2006). With respect to the second alteration, activating mutations in the 
FGFR3 gene are found in 74% of early low-grade bladder tumors (Billerey et al., 2001). 
When FGFR3 is mutated there is an increase in activation of the RAS-MAPK pathway. 
There is also an increase in activation of phospholipase Cγ which results in increased cell 
proliferation and survival ability (Di Martino et al., 2009).  
In MIBC there are many changes and rearrangements of both oncogenes and tumor 
suppressor genes. Similar to NMIBC, there is LOH on chromosome 9p as well as gain-of-
function mutations in FGFR3 in MIBC (Knowles, 2006). Additional mutations include 
changes in ERBB2, a tyrosine kinase of the Epidermal Growth Factor Receptor (EGFR) 
family (Gardiner et al., 1992). As with NMIBC, tumor suppressor genes are also altered in 
MIBC, including changes in p53, RB and CDKN2A/ARF (Knowles, 2006). However, the 
key alteration in the muscle invasive phenotype is the change in the PTEN pathway. 
Several studies have reported frequent LOH of chromosome 10, the location of PTEN, in 
MIBC (Cappellen et al., 1997; Kagan et al., 1998). PTEN is a known negative regulator of 
the key signaling pathway PI3K/AKT/mTOR and its loss or inactivation can result in 
increased AKT phosphorylation and activation (Houédé & Pourquier, 2015). The increase 
in AKT phosphorylation can activate many downstream effectors resulting in increased 
cell metabolism, growth, protein synthesis and increased cell survival ability (Hay, 2005). 
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Several studies have found that decreased PTEN expression is strongly associated with 
metastasis and poor survival across several cancer subtypes (Saal et al., 2007). Specifically, 
in MIBC the combination of PTEN and p53 loss often leads to aggressive disease (Puzio-
Kuter et al., 2009). 
EGFR and c-Met expression in BC 
In normal tissue, the binding of ligand to the EGFR results in dimerization with 
another EGFR molecule resulting in receptor activation. This will trigger intracellular 
signaling through several pathways such as the MAP kinase or AKT pathways which 
regulate many cellular functions including survival, proliferation or invasion (Black & 
Dinney, 2008). In tumor cells, EGFR activation will promote growth by increasing cell 
proliferation, motility, adhesion, invasive capacity and inhibiting apoptosis (Bellmunt et 
al., 2003). The level of expression of EGFR is altered in both NMIBC and MIBC with 50% 
of human tumors having an increase in EGFR (Bellmunt et al., 2003). EGFR expression 
levels have a significant correlation with recurrence and prognosis. In NMIBC, an increase 
in EGFR level was correlated with increased disease recurrence (Chow et al., 1997). In 
addition, the overexpression of EGFR is associated with adverse prognosis compared to 
BC with normal EGFR status (Mellon et al., 1995). Patients with advanced MIBC that 
expressed increased levels of EGFR had a much worse prognosis compared to patients with 
tumors with no EGFR expression (Nguyen et al., 1994). In addition to the effect of EGFR 
on cell growth, it also plays a key role in angiogenesis. Two key ligands of the EGFR, 
epidermal growth factor (EGF) and transforming growth factor-alpha, can increase the 
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secretion of vascular endothelial growth factor, a key pro-angiogenic protein (Bellmunt et 
al., 2003).  
Another protein which is also overexpressed in MIBC is mesenchymal epithelial 
transition factor (c-Met). c-Met is also a receptor tyrosine kinase (RTK) and is expressed 
in a variety of epithelial tissues in the body. Like EGFR, upon binding of its ligand, 
hepatocyte growth factor, c-Met will dimerize to activate intracellular pathways including 
ERK, AKT and PI3K (Hass et al., 2017). In addition, the overexpression of c-Met has been 
correlated with metastatic spread of many cancers including breast, liver and kidney 
cancers (Cheng et al., 2002). In BC, c-Met expression was found to be positively correlated 
with tumor grade and stage, with no expression in normal urothelial cells (Miyata et al., 
2009). Furthermore, the overexpression of c-Met is a strong indicator of a decrease in 
patient survival (Cheng et al., 2002).  
The EGFR and c-Met pathways are closely linked together and often activate 
similar pathways. Many tumors which initially respond to EGFR inhibitors will acquire 
resistance and demonstrate an increase in activation of the c-Met receptor (Wang et al., 
2012). This resistance has been observed in many cancers including colon, lung and breast 
(Liska et al., 2011). Following EGFR inhibition, the tumor cell will bypass this pathway 
and activate PI3K/AKT and MAPK pathways through c-Met activation (Zhang et al., 
2018). The crosstalk between these two receptors explains why a monotherapy does not 
completely stop tumor growth and a combination is needed to activate both pathways 
(Zhang et al., 2018). Blockade of both pathways results in a decrease in tumor volume and 
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proliferating cells compared to a single agent in a variety of cancer types (Castoldi et al., 
2013; Xu et al., 2011).  
Epigenetic modifications in BC 
In 2014, the Cancer Genome Atlas (TCGA) initiative evaluated 131 high-grade 
MIBC in order to find genetic and genomic alterations (Cancer Genome Atlas Research 
Network, 2014). In BC, many genes have been found to have genomic alterations including 
deletion, amplification and mutations of several genes (Cancer Genome Atlas Research 
Network, 2014). In addition, the results showed a significant subgroup of tumors (76%) 
presented with epigenetic modifications (Cancer Genome Atlas Research Network, 2014). 
Epigenetic modifications are changes to gene expression without alteration in DNA 
sequences, in contrast to genomic alterations in which regions of DNA are amplified, 
deleted or mutated (Kanwal et al. 2015). 
 Epigenetic modifications have been found throughout all cells in the body and are 
seen in several disease states, including cancer (Chen et al., 2014). There are three main 
types of epigenetic modifications: DNA methylation, histone modification, and non-coding 
Ribonucleic Acid (RNA). DNA methylation has been shown to be a major contributor to 
all types of cancer throughout the body (Akhavan-Niaki & Samadani, 2013). Specifically, 
DNA methylation of promoter regions of several cancer-related genes are found to be 
hypermethylated (Hoque et al., 2006; Maruyama et al., 2001). DNA methylation is a stable 
modification which is produced during DNA replication. In eukaryotes, DNA methylation 
occurs on cytidine residues in sequences 5’CG3’ or CpG dinucleotide (Akhavan-Niaki & 
Samadani, 2013). These CpG regions are not found throughout DNA but rather located in 
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specific sections called CpG islands (Ioshikhes & Zhang, 2000). Interestingly, CpG islands 
are found in 50% of the promoter regions of human genes, including both housekeeping 
and specific genes (Ioshikhes & Zhang, 2000). Normally, CpG islands located in the gene 
promoter are unmethylated, which allows for the gene to be active and DNA transcribed. 
Methylation of a gene can interfere with the transcriptional machinery interacting with the 
DNA and thus inhibit transcription (Figure 1A). This mechanism is used by tumor cells to 
silence many genes including tumor suppressor genes such as p16. DNA methylation is 
believed to occur early in tumor cell transformation and could facilitate tumorigenesis, as 
DNA hypermethylation has been seen in pre-neoplastic lesions in breast, colon and many 
other cancers (Gokul & Khosla, 2013). Wolff et al. examined a variety of genes in both 
NMIBC, MIBC and normal tissue from similarly age patients and found that in MIBC 38% 
of loci were hypermethylated compared to only 10% in NMIBC (Wolff et al., 2010). 
 The second major group of epigenetic modifications occur on histone proteins, and 
include acetylation, phosphorylation or methylation. Histones are a part of the DNA 
packaging unit called a nucleosome which involves a sequence of DNA that is wrapped 
around 2 subunits each consisting of histone proteins H2A, H2B, H3 and H4 (Hoffman & 
Cairns, 2011). The histones have a tail region which is accessible to covalent modifications. 
Two key proteins, histone acetyltransferases (HAT) and histone deacetylases (HDAC), are 
the enzymes which add or remove acetyl groups respectively. The addition of an acetyl 
group can neutralize the positive charge on the histone allowing a relaxed conformation 
and promoting gene transcription (Barneda-Zahonero & Parra, 2012) (Figure 1B). Histone 
methylation is mediated by histone methyltransferases (MT). In BC, there has been found 
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to be altered histone modification in 89% of cases (Cancer Genome Atlas Research 
Network, 2014). For example, Enhancer of Zest Homolog 2, an MT and a common 
oncogene, is overexpressed in BC and is associated with more aggressive tumors (Wang et 
al., 2012). In BC there is also an altered expression of HDAC, which is overexpressed 
compared to normal tissue (Tanji et al., 2011).  
 
Figure 1. Schematic depicting epigenetic modifications. (A) The same gene is shown in 
two different conditions. During the normal state, the gene promoter is hypomethylated 
resulting in increased transcription of the exon. However, during cancer, the gene promoter 
becomes hypermethylated resulting in no gene transcription. The switch from hypo- to 
hyper-methylation status is completed by DNMTs. (Figure adapted from Kandimalla et al., 
2013) (B) Histone modifications where the addition of acetyl groups by HAT cause histone 
relaxation and increased gene transcription or the removal of acetyl groups by HDACs 
cause histone compression and decreased gene transcription. (Figure adapted from 







SH3GL2/Endophilin-A1 and BC 
SH3GL2/endophilin A1 was originally discovered in relation to its function in the 
brain, aiding in synaptic vesicle recycling (Ringstad et al., 1997). SH3GL2 is a major 
component of the endophilin-CIN85-Cbl complex which regulates recycling and therefore 
signaling of EGFR and c-MET (Petrelli et al., 2002; Soubeyran et al., 2002). Following 
EGFR/c-MET binding to their respective ligands and phosphorylation of tyrosine residues 
on the RTK, the phosphorylated receptor recruits the protein Cbl (Oved & Yarden, 2002), 
a ubiquitin ligase. Cbl ubiquitinates the receptor which triggers recruitment of the adaptor 
protein CIN85 which in turn will recruit SH3GL2 (Soubeyran et al., 2002). Once the 
complex is attached to the RTK, it changes the curvature of the plasma membrane in which 
the receptor is located leading to endocytosis and inactivation of the receptor (Oved & 
Yarden, 2002) (Figure 2A). 
 
Figure 2. SH3GL2/Endophilin is involved in receptor recycling and degradation. (A) 
A cartoon schematic of the function of SH3GL2 function after growth factor binding to 
receptor. After binding, SH3GL2 will associate with Cbl and CIN85 to trigger receptor 
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endocytosis of the active growth receptor which either results in receptor recycling or 
degradation. (Figure 2A adapted from Oved & Yarden, 2002). (B) Immunofluorescence 
staining of cells after EGF treatment. In the control cells, after EGF binding, the EGFR 
undergoes internalization shown by merge of coloring of the red and blue. In cells with 
SH3GL2 knocked down, the EGFR remains on the surface after EGF treatment (published 
data from Majumdar et al., 2013.). 
 
Recently our laboratory found that SH3GL2 was enriched in the bladder and the 
loss of function of SH3GL2 in BC was discovered to be an important regulator of the 
oncogenic activity of BC and had a role in tumor suppressor (Majumdar et al., 2013). The 
gene encoding SH3GL2 is located on chromosome 9p (9p22) (Majumdar et al., 2013), a 
known hotspot of genetic alterations in BC. Interestingly, p16, a gene lost frequently in 
BC, is located at 9p21. Several studies have found distal deletions of chromosome 9p 
relative to the p16 gene locus (Keen & Knowles, 1994; Pollock et al., 2001). Analysis of 
human tumors, found that with BC progression from superficial to invasive BC there is a 
significant decrease in mRNA and protein level of SH3GL2 and its loss appears to be a 
frequent phenomenon in BC pathogenesis (Majumdar et al., 2013). Additionally, when 
SH3GL2 was knocked down in BC cell lines there was an increase in EGFR on the surface 
following EGF treatment which resulted in increased growth and proliferation in both in-
vitro and in-vivo experiments (Majumdar et al., 2013) (Figure 2B). These results indicate 
that the loss of SH3GL2 constitute a mechanism for EGFR, c-Met kinase activation in BC. 
Apart from BC, SH3GL2 changes are also found in several other cancers. In breast 
cancer, a decrease in SH3GL2 is found as an early event in tumorigenesis (Sinha et al., 
2008). Lung and head and neck cancers also have reduced SH3GL2 which leads to 
increased EGFR expression and increased cell growth (Dasgupta et al., 2013;  Maiti et al., 
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2013). The mechanism of silencing of SH3GL2 in breast cancer and several other cancers 
is through DNA methylation (Li et al., 2015; Sinha et al., 2008). Whether the loss of 
SH3GL2 in BC also occurs as a result of DNA methylation is unknown.  
The overall goal of this study is to investigate the mechanisms of SH3GL2 silencing 
in BC cell lines. More specifically, the hypothesis is that pharmacological demethylation 
of the promoter together with inhibition of HDAC activity, will lead to re-expression of 
SH3GL2. To test this hypothesis two aims were explored. 
Aim I: 
To examine the methylation status of SH3GL2 in a variety of different BC cell 
lines. 
Aim II: 
A. To explore the required dose of DNA demethylating agents and HDAC 
inhibitor needed to minimize apoptosis. 
B. To determine if demethylation along with an HDAC inhibitor is sufficient to 





Cell culture, chemicals and antibodies 
  253J and J82 BC cell lines were grown in Minimal Essential Media (MEM) cell 
culture media (Life Technologies, Carlsbad, CA) containing 10% fetal bovine serum (FBS) 
(Corning, Tewksbury, Massachusetts), 1% L-Glutamine Solution (L-Glut), 1% 10,000 
U/mL Penicillin-Streptomycin Solution (P/S) (both from Life Technologies, Carlsbad, CA) 
and 1% MEM Non-Essential Amino Acids Solution (100x) (Life Technologies, cat# 
11140050, Carlsbad, CA). RT4 and T24 cells were cultured in McCoy’s 5A (modified) 
Medium cell culture media (Life Technologies, Carlsbad, CA) containing 10% FBS, 1% 
L-Glut and 1% P/S. All cells were incubated at 37° Celsius (C) and 5% Carbon Dioxide 
(CO2). 5-Aza-2’-deoxycytidine (Decitabine) (5-Aza-dC) was purchased from Sigma-
Aldrich (cat # A3656, St. Louis, MO) and stocks of 50 millimolar (mM) were prepared in 
dimethyl sulfoxide (DMSO) (Sigma-Aldrich, cat# TS-20688, St. Louis, MO). Trichostatin 
A (TSA) was purchased from Sigma-Aldrich (cat# T1952, St. Louis, MO). Zebularine 
(cat# 10975, Ann Arbor, MI) and RG-108 (cat# 13302, Ann Arbor, MI) were purchased 
from Cayman Chemical. 50mM stocks of each drug were prepared in DMSO and stored at 
-80°C.  
 The following antibodies were used: primary antibody for SH3GL2 was a mouse 
monoclonal antibody (clone 4D12, Santa Cruz Biotechnology, cat# sc-134329) at a dilution 
of 1: 10,000 in Phosphate Buffered Saline/Tween (PBS/T). β-Actin antibody was a 
monoclonal mouse antibody (Thermofisher, cat# MA5-15739) at a dilution of 1: 10,000 in 
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PBS/T/5% non-fat dried milk. Horseradish peroxidase (HRP)-conjugated anti-mouse 
secondary antibodies were used (Thermofisher, cat# 32430, Carlsbad, CA) at a dilution of 
1: 20,000 in 10% milk/ PBS/T solution. 
5-Aza-dC and TSA treatment of cells 
 Initially, 253J or T24 cells were cultured and 50,000 (253J) or 25,000 (T24) cells 
were counted and seeded into a 6-well plate (Corning, cat# 353046, Tewksbury, 
Massachusetts). After overnight incubation at 37°C, stock 5-Aza-dC was diluted in culture 
media and added at different concentrations to the medium and incubated at 37°C for 
varying times depending on the experiment. At the end of the incubation, 500µL of TRIzol 
Reagent (Life Technology cat# 15596026, Carlsbad, CA) was added to lyse the cells. 
Samples were frozen at -80°C. 
 After determining the appropriate dose to minimize toxicity, 50,000 253J cells were 
seeded and the repeat experiment was conducted with the addition of the proper 
concentrations of 5-Aza-dC and incubated for 48 hours. TSA was then added and incubated 
for an additional 24 hours. DMSO was added to the cells in the appropriate volume as a 
control. After treatment with TSA for 24 hours the medium was removed and 500µL of 
TRIzol Reagent was added to lyse the cells. Samples were frozen at -80°C. 
Zebularine and RG-108 treatment of cells 
 Initially, 253J cells were cultured and 75,000 cells were counted, seeded into a 6-
well plate and incubated overnight at 37°C. Using the protocol outlined in previous 
experiments using Zebularine (Cheng et al., 2004) 500µM was added to either 253J or T24 
cells for 72 hours. Cells were then observed under a microscope to observe toxicity. Using 
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a similar procedure, cells were initially plated overnight at which point RG108 was then 
added at 500 µM to the medium and incubated at 37°C for varying times depending on 
experimental conditions. Cells were then harvested in 500µL of TRIzol reagent. Samples 
were frozen at -80°C.  
RNA isolation and cDNA synthesis 
 The frozen samples were thawed and 100µL of chloroform was added. The 
solutions were vortexed and then centrifuged at 12,000 rpm at 4°C for 15 minutes, after 
which the top clear aqueous layer was removed and added to 200µL of 70% ethanol. This 
mixture was added to RNeasy spin columns (RNeasy kit, Qiagen, cat #74104, 
Germantown, MD) and centrifuged for 15 seconds at 10,000 rpm. Columns were washed 
with 700µL of wash buffer from the kit and centrifuged for 15 seconds at 10,000 rpm. Two 
additions of 500µL of RPE buffer from the RNeasy kit were added with 15 seconds and 2 
minutes of centrifuging respectively after each addition. The spin column was air-dried for 
10 minutes and 30µl of nuclease-free water (Qiagen, cat# 129114, Germantown, MD) was 
added to the column to elute the RNA. The column was added to a new centrifuge tubes 
and centrifuged for 2 minutes at 10,000 rpm at 4°C to collect eluted RNA. Purified RNA 
was quantified using a Nano-drop, and concentration and purity were obtained using 
absorbance of 260/280 as readouts. If impure RNA was obtained, an additional 30µL of 
nuclease-free water was added and re-centrifuged to improve RNA purity.  
 Depending on the yield of RNA from the isolation, a range of input RNA (175-
1000ng) was added to the Reverse Transcription (RT) reaction to maximize cDNA yield. 
The Bio-Rad iScript cDNA synthesis Kit (cat# 1708891, Hercules, CA) was used in which 
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each 20µL reaction comprised 4µL of 5x iScript Reaction Mix, 1µL of iScript Reverse 
Transcriptase, RNA and nuclease-free water, depending on RNA concentrations in 
individual samples. Samples were incubated in a thermocycler for 5 minutes at 25°C for 
priming, 20 minutes at 46°C for RT and 1 minute at 95°C for RT inactivation. 20µL of the 
cDNA was diluted into 480µL of nuclease-free water and stored at -20°C. 
Quantitative RT-PCR 
 A MicroAmp 96-well reaction plate (Thermofisher Scientific, cat# 4346907) was 
used for the quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR). 
Each cDNA sample was run in triplicate. A reaction mixture in the ratio of 10:1 of TaqMan 
Universal PCR Master Mix (Thermofisher Scientific, cat# 4304437) to TaqMan probe was 
used. The probes included SH3GL2 (Thermofisher Scientific cat# 4331182 Assay ID: 
Hs00182352_m1), and β-Actin (Thermofisher Scientific, cat# 4331182, Assay ID: 
Hs01060665_g1). For each sample 11µL of the reaction mixture was added to each well, 
followed by 9 µL of the cDNA dilution. β-Actin was used as the house-keeping gene. The 
reaction plate was loaded into the StepOnePlus Real-Time PCR System. The PCR protocol 
was: 10 minutes at 95°C to activate the DNA polymerase followed by a two-step cycle of 
95°C for 15 seconds, which allows the DNA to separate and 60°C for 1 minute which 
allows probe annealing. These two steps were repeated for 40 cycles to help amplify the 
gene of interest. The final read-out was a CT which was used in further calculations. 
Methylation analysis 
 Previously isolated genomic DNA from a variety of BC cell lines were generated 
using the Qiagen DNeasy kit protocol (cat# 74104, Germantown, MD). DNA was 
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quantified using Nano-drop where concentration and purity were assessed. Dilutions of 
genomic DNA were made in nuclease free water to yield 25ηg of genomic DNA. A 
reaction cocktail of 5µL of genomic DNA (125ng), 13µL of 5x Restriction Digestion 
Buffer from the Epitect Methyl II DNA Restriction Kit (Qiagen, cat# 335452, 
Germantown, MD) along with 42µL of nuclease-free water was generated. Four separate 
restriction enzyme digestions were set up. 14 µL of the reaction cocktail was added to each 
reaction as follows: 
1. Mock digest (Mo) with no restriction enzyme 
2. A methylation-sensitive restriction digest (Ms) 
3. A methylation-dependent restriction digest (Md) 
4. A double digest (Msd) where both the methylation-sensitive and dependent 
enzymes were added 
All reactions were incubated at 37°C for 6 hours in a thermocycler in order to activate the 
enzymes. After incubation the reactions were heated to 65°C for 20 minutes in order to 
heat inactivate enzymes. 
 To determine the degree of methylation by qPCR, 5µL of each digest was added to 
a well in a MicroAmp 96-well reaction plate along with 12.5µL of RT2 SYBR Green 
Mastermix (Qiagen, cat# 330500, Germantown, MD), 1µL of a SH3GL2 Primer (Qiagen, 






Each sample was run in duplicate on the plate. The PCR was performed to obtain raw CT 
values and cycled per the Epitect Methyl II DNA protocol: 
Temperature Time Number of Cycles 











A melting curve was also performed after the cycling program to ensure specificity of 
primers. The results were then exported into the Qiagen Methylation analysis software. 
Immunoblot analysis 
 
40,000 J82 cells were seeded into four 6 cm dishes and allowed to adhere overnight 
at 37°C. The next day vehicle control (DMSO) and drugs (Zebularine, RG108 or 5-Aza-
dC) were added to each dish and incubated for various times at 37°C. Following drug 
exposure, the media was then removed and washed twice with 3mL of ice cold PBS (Life 
Technology, cat# 10010023, Carlsbad, CA). Depending on cell confluence at the time of 
harvest either 100 or 150 µL of cell lysis buffer (Cell Signalling, cat# 9803, Danvers, MA) 
with protease inhibitor cocktail (Thermofisher, cat# 78429, Carlsbad, CA) was added on 
ice. After 15 minutes, cells were scraped and lysates collected. Protein concentrations were 
determined using the MicroBCA protein assay (Thermofisher Scientific, Cat# 23235, 
Carlsbad, CA) to determine the appropriate amount of protein to add to the separating gel. 
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Following the protein assay, separating gels (distilled water (dH2O), 30% 
Acrylamide mix, 1.5M Tris (pH 8.8), 10% SDS, 10% APS, TEMED) and stacking gel 
(dH2O, 30% Acrylamide mix, 1M Tris (pH 6.8), 10% SDS, 10% APS, TEMED) were 
prepared. For each sample 4x sample buffer (100% glycerol, 1M Tris-HCl, 20% SDS, 1% 
Bromophenol blue and dH2O) and β-Mercaptoethanol was added and the samples were 
boiled for 10 minutes. After the gels polymerized, they were added to the electrode 
apparatus and running buffer (dH2O, Tris base, glycine and 0.1% SDS) was added. 
Appropriate amounts of protein were then added to specific wells. The gel was run at 100V 
to allow samples to pass through the stacking gel, and then at 160V for 75 minutes. When 
finished, the stacking gel was removed. The gel was placed in a tray with transfer buffer 
(dH2O, Tris base, glycine and 20% methanol) for 15 minutes to shrink gels prior to transfer. 
Assembly of the transfer cassette was performed and the transfer apparatus was filled with 
transfer buffer and an ice pack. The transfer was run overnight at 50V in the cold room. 
The next morning, the voltage was increased to 100V for an additional hour. Following the 
transfer, the membranes were washed in dH2O and then stained with Ponceau S dye to 
verify equal transfer and protein loading. The membranes were rinsed in dH2O and imaged 
on a flat-bed scanner. After rinsing in PBS/T (10x PBS, 10% Tween-20 Solution and 
dH2O), membranes were incubated in a solution of PBS/T and 10% milk for 1-hour at room 
temperature to block non-specific binding sites. Primary antibodies to proteins of interest 
were added and incubated overnight at 4°C. The membranes were then washed 3 times 
with PBS/T. Species-specific secondary antibodies, were added and allowed to incubate 
for 1-hour at room temperature. Membranes were washed again 3 times in PBS/T. To 
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detect proteins, membranes were incubated with SuperSignal West Pico PLUS 
Chemiluminescent Substrate (Thermofisher Scientific, cat# 34580, Carlsbad, CA). Equal 
volumes of Luminol and Peroxide solutions from SuperSignal kit were mixed and added 
to membranes for 5 minutes at room temperature. Membranes were then exposed to X-ray 
film for variable times in the dark room to visualize signals.  
Statistical analysis 
 
 The output of all qRT-PCR reactions were Ct values. These Ct values were then 
normalized to the housekeeping gene, β-actin, to find the difference between the Ct values 
of each condition to its respective β-actin level yielding ΔCt. The average ΔCt of the 
vehicle control was then calculated and subtracted from each ΔCt yielding ΔΔCt. ΔΔCt was 
then analyzed using 2^(-ΔΔCt) in order to find the relative gene expression value. All graphs 





 SH3GL2 is normally expressed in the urothelium of the bladder and has previously 
been shown to have a major role in BC and its oncogenic properties (Majumdar et al., 
2013). SH3GL2 is key in the regulation of EGFR and c-Met signaling and when it is lost, 
it leads to increased activation of EGFR in BC (Majumdar et al., 2013). Given the initial 
data suggesting little or no SH3GL2 mRNA or protein expression in the majority of BC 
cell lines and the inverse relationship between SH3GL2 DNA promoter methylation and 
mRNA expression (Figure 3), the hypothesis that promoter methylation is a likely 
mechanism to explain the lack of expression was explored. In addition, the potential for re-
expression of SH3GL2 mRNA and protein using pharmacological approaches was also 
investigated.  
Methylation status of SH3GL2 in BC cell lines 
 Our laboratory found that in many BC tumor cell lines, there was little or no 
SH3GL2 expression at the mRNA or protein level (Figure 3A and B) (Data from Majumdar 
et al., 2013). Reports in the literature describe promoter methylation as a mechanism for 
downregulation of SH3GL2 expression (Li et al., 2015; Sinha et al., 2008). To explore this 
hypothesis a bioinformatics approach was used analyzing data from the Cancer Cell Line 
Encylopedia (CCLE) (Figure 3C). This data showed a strong inverse correlation between 
DNA methylation and mRNA expression of SH3GL2 (Figure 3C). To determine the extent 
of SH3GL2 promoter methylation in BC, genomic DNA was isolated from a panel of BC 
cell lines and methylation-specific digestion and qPCR were performed. This demonstrated 
that RT4, 5637, TCCSUP and HTERT cell lines had close to a 100% unmethylated 
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promoter while the T24 and 253J cell lines have almost 100% promoter methylation 
(Figure 3D). Interestingly, the SH3GL2 promoter region was approximately 30% 
unmethylated in the J82 cell line (Figure 3D). In T24 and 253J cells the high level of 
methylation is consistent with gene silencing shown with no mRNA and protein expression 
of SH3GL2 (Data from Majumdar et al., 2013) (Figure 3). However, several cell lines 
5637, TCCSUP and hTERT, which do not express SH3GL2 (Figure 3A and B) but do have 
an unmethylated promoter region suggests that methylation is not the only mechanism of 
silencing. 
 
Figure 3. Promoter methylation affects mRNA and protein expression of SH3GL2. 
(A) qRT-PCR analysis of SH3GL2 mRNA in a variety of BC tumor cell lines. Only RT4 
had high gene expression (published data, contributed by Majumdar et al., 2013). (B) A 
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immunoblot analyzing SH3GL2 protein levels in a variety of BC tumor cell lines 
(published data, contributed by Majumdar et al., 2013). (C) A scatter plot of SH3GL2 
mRNA data compared to SH3GL2 promoter DNA methylation. A strong negative 
correlation exists between mRNA levels and DNA methylation (Spearman ρ=-0.487) 
(Data taken from https://portals.broadinstitute.org/ccle). (D). Methylation analysis of 
genomic DNA isolated from a variety of BC tumor cell lines. Genomic DNA was digested 
based upon protocol from the Epitect Methyl II DNA Restriction Kit and analyzed by 
qPCR. CT values were then analyzed using Qiagen Methylation analysis software. 
 
To explore if this method of silencing was seen beyond BC cell lines, the TCGA 
database was used to conduct an informatics-based analysis of expression and methylation 
of SH3GL2 from human BC tissue (Figure 4). This analysis was from 4 different DNA 
methylation sites on the SH3GL2 gene and a significant negative correlation between DNA 
methylation and SH3GL2 mRNA expression levels in BC was found. While a few cases 
showed genomic gains (orange circles) or losses (purple) the majority of cases showed the 
SH3GL2 gene unaltered by genomic rearrangements but rather showed silencing through 
DNA methylation (Figure 4). The genomic losses (purple circles) could explain the 
mechanism of silencing in 5637, TCCSUP and hTERT cell lines. This data illustrates a 




Figure 4. DNA methylation correlation with SH3GL2 mRNA expression. TCGA data 
of 228 human BC tumors analyzing the association between DNA methylation and mRNA 
expression of SH3GL2. Analysis is from 4 promoter sites. A strong negative correlation 
(Spearman ρ=-0.302) exists in human BCs with only a few numbers of tumors having 
genomic changes (orange: genomic gains and purple/turquoise: genomic losses). (Data 
generated by the TCGA Research Network: http://cancergenome.nih.gov) 
  
Demethylating agents promote gene reactivation 
 Given the previous observation that SH3GL2 was silenced in several BC cell lines 
and having observed a negative correlation in human BC tissues from TCGA, the ability 
to reactivate the gene in 253J and T24 BC tumor cells was explored. Several demethylating 
agents: 5-Aza-dC, Zebularine and RG108 were explored as to their ability to reactivate 
SH3GL2. Initially, 5-Aza-dC was used as this was a known cytidine analog that can be 
incorporated into DNA of cells leading to loss of DNMT activity due to the enzyme 
becoming permanently bound to the cytidine analog (Christman, 2002) (Figure 5A). 
However, like most DNA modifying agents, the drug can be toxic to cells and cause them 
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to undergo apoptosis. As a result, a dose-response was performed to determine the optimal 
dose that did not lead to cell toxicity (Figure 6A). Cell toxicity was observed by looking at 
cells under a microscope and assessing phenotype and adherence. From this result and 
previous experiments (unpublished data, Majumdar et al., 2013) a starting dose of 20µM 
was selected. After adding 5-Aza-dC at the appropriate dose, T24 cells exhibited a relative 
fold increase in SH3GL2 mRNA levels of 11.68 compared to vehicle control (1.48) 
analzyed through qRT-PCR (Figure 6B). We expanded this experiment to 253J cells using 
the same dose of 5-Aza-dC and were also able to see an increase of SH3GL2 expression 
(11.66) compared to vehicle control (1.38) (Figure 6B).  
 The largest issue encountered in these expeirments was the problem of 5-Aza-dC 
stability in aqueous solution. Previous literature has shown that 5-Aza-dC is toxic and 
unstable in aqueous solutions which could complicate its use clinically (Cheng et al., 2004). 
As a result, another drug, Zebularine was tested. Zebularine is also an inhibitor of DNA 
methylation but is much more stable in aqueous solution and was proven effective in an in-
vivo model (Cheng et al., 2003). Similarly to 5-Aza-dC, Zebularine is a cytidine analog 
which forms a complex with DNMT, thereby inhibiting their function (Cheng et al., 2003) 
(Figure 5A). As a result, a dose-response was performed using 253J to assess maximum 
gene reactivation with minimum cell toxicity. Taking into combination the toxicity 
observed under a microscope (floating cells) and the relative fold increase (7.19 times) in 
gene expression (Figure 7A), a dose of 500µM was selected. When compared to control 
(1), this was able to increase gene expression (9.21) (Figure 7B). However, when T24 cells 
were treated with Zebularine at the same dosage, we were only able to get a slight increase 
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in gene activation compared to vehicle control (7B). Thus, the findings suggest that 
Zebularine is a valid alternative in selected cell lines and has much higher stability in 
solution compared to 5-Aza-dC.  
 
 
Figure 5. Mechanism of action of the three drugs used in this study. (A) Both 5-Aza-
dC and Zebularine are cytidine analogs which will intercalate into DNA and covelently 
bind to DNMTs inhibiting their function. The R group represents the different functional 
groups between 5-Aza-dC and Zebularine. (B) RG-108 acts as an inhibitor of DNMT and 
will interact with the active site of the DNMT. (Figure adapted from Lyko & Brown, 2005) 
 
 Finally, to explore another method of gene reactivation, the drug RG-108 was 
tested. RG-108 is a direct methyltransferase inhibitor which does not covalently attach to 
the methyltransferase but rather will block the active site of DNA Methytransferase 1 
(Figure 5B). This modification was made in order to limit toxicity to cells, as covalent 
modifications, as seen with 5-Aza-dC and Zebularine, were found to be toxic to the cells. 
Similarly to Zebularine, 500 µM was selected as the optimal dose to have gene reactivation 
while minimizing cell toxicity. However, unlike either 5-Aza-dC and Zebularine, RG-108 
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at this dose was unable to increase gene expression in either 253J or T24 cells (Figure 7C). 
Overall, these results indicate a stronger agent that directly binds as a cytidine analog rather 
than a competitive inhibitor is required to increase the expression of SH3GL2.  
 
Figure 6. Effect of 5-Aza-dC on SH3GL2 expression (A) A dose-response of T24 cells 
exposed to a variety of 5-Aza-dC concentrations. T24 cells were grown for 24hrs and then 
treated with different 5-Aza-dC concentrations for 120 hrs. Cells were harvested and gene 
expression was detected by qRT-PCR. Error bars indicate standard deviation between 
technical triplicates. (B) The effect of 5-Aza-dC at a dose of 20µM on T24 and 253J cells. 
Both cell lines were grown for 24hrs after which 5-Aza-dC was added to the cells for 
120hrs. Cells were harvested and gene expression was detected by qRT-PCR. Error bars 




Figure 7. Effect of Zebularine and RG-108 on SH3GL2 expression. (A) A dose-
response of 253J cells exposed to a variety of Zebularine concentrations. 253J cells were 
grown for 24hrs and then treated with different Zebularine concentrations for 72 hrs. (B) 
The effect of Zebularine at a dose of 500µM to T24 and 253J cells. Both cell lines were 
grown for 24hrs after which Zebularine was given to the cells for 72hrs. (C) The effect of 
RG-108 at a dose of 500 µM to T24 and 253J cells. Both cell lines were grown for 24hrs 
after which RG-108 was given to the cells for 96hrs. In all three figures cells were harvested 
and gene expression was detected by qRT-PCR. Error bars indicate standard deviation 
between technical triplicates. 
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Combining demethylation and histone deacetylation inhibitor further increases gene 
activation  
After observing that 5-Aza-dC was able to reverse silencing and increase SH3GL2 
mRNA levels, the extent to which SH3GL2 protein could be re-expressed was also 
explored. Published literature suggests that demethylating agents alone are often not 
sufficient to achieve protein re-expression and that additional manipulation of the 
epigenetic machinery, namely histone modifications are required. On top of DNA 
methylation, a common silencing method in many cancer cells is histone deacetylation. In 
BC specificially, HDAC is overexpressed compared to normal tissue (Tanji et al., 2011). 
In these experiments, the HDAC inhibitor TSA, was used alone and in combination with 
5-Aza-dC to try and induce protein expression. Using TSA along with 5-Aza-dC is a known 
mechanism as the two drugs have been shown to work synergistically to reactivate genes 
(Cameron et al., 1999). However, initial experiments showed the combination of drugs was 
very toxic to cells and as a result a lower dose (10µM) of 5-Aza-dC was needed along with 
a low dose of TSA (75ηM). This combination increased gene expression by an average 
8.62-fold compared to vehicle control (Figure 8). However, TSA alone was not sufficient 
to reactivate expression of SH3GL2. In fact the expression of SH3GL2 decreased after 
addition of TSA compared to the control (Figure 8). These results indicate that the 
combination of 5-Aza-dC along with TSA was sufficient to further increase gene activation 
compared to 5-Aza-dC alone (Figure 8) and could be used as a potential strategy to 




Figure 8. Effect of 5-Aza-dC and TSA on SH3GL2 mRNA levels. 253J cells were grown 
for 24hrs and then treated with 10µM of 5-Aza-dC for 48hrs. After which 75ηM of TSA 
was added and cells were allowed to grow for an additional 24hrs. After which cells were 
harvested and gene expression was found using qRT-PCR. Error bars indicate standard 
deviation between technical triplicates. 
 
Demethylating agents effect on protein expression 
 In order to determine whether the three demethylating agents could increase protein 
levels, immunoblot analysis for SH3GL2 protein was performed using the J82 cell line. In 
J82 cells the extent of SH3GL2 promoter methylation is approximately 70% (Figure 3D). 
Interestingly, a small amount of SH3GL2 protein was detectable in J82 cells (Figure 3B, 
contributed by Majumdar et al., 2013), suggesting that this level could be increased by 
promoter demethylation. Consequently, J82 cells were exposed to the three demethylating 
agents, 5-Aza-dC (20µM), Zebularine (500µM) and RG-108 (500µM). SH3GL2 protein 
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expression was analyzed through immunoblot with RT4 used as a positive control. From 
the immunoblot, all three drugs were able to increase SH3GL2 protein levels above that 
observed in the untreated and vehicle control (DMSO) (Figure 9). Overall, these results 
indicate that demethylating agents can increase both mRNA and protein levels in J82 cells. 
 
Figure 9. Demethylating agents effect on SH3GL2 protein expression. J82 cells were 
treated with 5-Aza-dC (20µM) for 48hrs with fresh drug added every 24hrs, after which 
the media was changed and cells were incubated for an additional 72 hrs. Zebularine 
(500µM) was given for 48hrs after which fresh media was added and cells were incubated 
for an additional 96hrs. RG-108 (500µM) was given for 96 hrs. Following addition of the 
chemiluminescent reagent, film was exposed to membranes for 1 hr. RT4 cells were used 
as a positive control. β-actin was used as a loading control. 
 
Effect of reactivation of SH3GL2 on BC cells 
 While increasing SH3GL2 at the mRNA level is important to re-express the protein, 
it is important to determine how this re-expression affects tumor cell behaviour. To observe 
the impact of re-expression of SH3GL2 on tumor cell behaviour two key properties were 
explored: cell migration and growth. The re-expression of SH3GL2 was performed using 
viral re-expression in T24 cells (Figure 10A) (Data from Majumdar et al., 2013). This re-
expression of SH3GL2 was able to decrease proliferation to a statistically significant extent 
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compared to cells transduced with virus encoding an irrelevant gene (LacZ) (Figure 10B). 
To assess the effect of SH3GL2 re-expression on cell migration, a migration assay was 
performed in the presence of EGF. When SH3GL2 was re-expressed, EGF-stimulated 
migration of T24 cells decreased by greater than 50% (Figure 10C). Overall, the re-
expression of SH3GL2 had a major effect on two key tumor cell properties and can be seen 









Figure 10. Re-expression of SH3GL2 slows tumor growth and migration. (A) A 
immunoblot confirming the re-expression through viral transduction of SH3GL2 in T24 
BC tumor cells. (B) Relative growth of T24 cells following transduction with SH3GL2 or 
an irrelevant gene (LacZ). T24 cells re-expressing SH3GL2 showed significantly less 
proliferation after 48hrs compared to LacZ expressing cells. (*, P<0.05). (C) A migration 
assay showing the slowing of EGF-stimulated migration in T24 cells re-expressing 
SH3GL2 compared to those expressing LacZ. The graph represents distance migrated with 
SH3GL2-expressing cells migrating significantly less than LacZ-expressing cells (P<0.05). 






 This study describes the mechanism of SH3GL2 silencing in BC and how it could 
be re-expressed in BC cells. Using a panel of BC cell lines, it was demonstrated that: 1) 
the SH3GL2 promoter was hypermethylated to differing extents in different cell lines; (2) 
in several cell lines the extent of promoter methylation correlated inversely with mRNA 
and protein expression; (3) evaluation of data from the CCLE and TCGA initiatives 
verified the inverse relationship between SH3GL2 promoter methylation and expression; 
(4) treatment with demethylation agents induced re-expression of SH3GL2 mRNA and 
protein. Together, these findings provide a mechanism to increase SH3GL2 levels and a 
way to attenuate tumor cell growth beyond common treatments. 
 The mechanism of silencing was confirmed by looking at the methylation status of 
SH3GL2 promoter in several BC tumor cell lines. These findings were further supported 
when three different demethylating agents were added to methylation silenced BC tumor 
cell lines. This resulted in an increase in SH3GL2 mRNA levels, indicating that this was 
the mechanism of silencing. SH3GL2 silencing is found beyond BC. SH3GL2 was also 
found to be silenced through DNA methylation in breast and vulvar carcinoma (Sinha et 
al., 2008; Li et al., 2015). Interestingly, this relationship between methylation status and 
the gene expression does not hold in two BC tumor cell lines, TCCSUP and 5637 tumor 
cell lines. In addition, hTERT cells also exhibit no methylation of SH3GL2 with no protein 
expression. Previous studies on hTERT cells have analyzed their 9p status and found it to 
be homozygously deleted (Kim et al., 2011). In addition to hTERT cells, this homozygous 
deletion could also be found in TCCSUP and 5637 and explain the lack of SH3GL2 
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expression with low DNA methylation. Other changes could also include post-
transcriptional changes such as mRNA and protein degradation. However, more research 
is needed to confirm this hypothesis. In human BC samples, while the majority of samples 
showed methylation changes to SH3GL2 there were several samples which exhibited a 
genomic change to the SH3GL2 gene, which would explain the lack of methylation with 
no gene expression in the cell lines. Therefore, while DNA hypermethylation may be the 
dominant mechanism for SH3GL2 silencing, genomic alteration could be an alternative 
mechanism in specific BC tumors. 
 In this work, three different demethylating drugs with three distinct mechanisms of 
action were used to assess the ability to reactivate silenced SH3GL2. Interestingly, each of 
the three drugs displayed differences in dose required for gene activation while minimizing 
cell toxicity. The instability of 5-Aza-dC in aqueous solution has been well documented 
and was a major limitation in this work as the half-life of 5-Aza-dC at 37°C was 20 hours 
(Stresemann & Lyko, 2008). Hence, for certain experiments, 5-Aza-dC was not able to 
reactivate the gene of interest. A possible explanation would be the lack of stability in 
aqueous solution. This lack of stability has led many researchers to utilize continuous 
addition of 5-Aza-dC in order to trigger its demethylating effects (Samlowski et al., 2005). 
However, this method was proven to be toxic in this work and therefore was not utilized to 
trigger gene reactivation. By virtue of this instability, a different drug, Zebularine was used. 
Like 5-Aza-dC, Zebularine is a cytidine analog that also binds to and inhibits DNMT’s 
function. The benefit of using Zebularine is its high stability in aqueous solution, with a 
half-life of 508 hours at 37°C (Champion et al., 2010). Unlike 5-Aza-dC, a much higher 
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dosage of Zebularine was required to trigger gene reactivation. A dose of 5-Aza-dC at 20 
µM was equal to 500µM reactivation ability. This result is consistent with previous 
published data which explored the reactivation of silenced p16 in T24 cells where 500µM 
of Zebularine compared to a dose of 30µM of 5-Aza-dC was required to reactivate silenced 
p16 gene in BC cells (Cheng et al., 2003). In contrast to 5-Aza-dC, the cells were able to 
tolerate the increased dose of Zebularine, such that this drug was a viable alternative to the 
instability of 5-Aza-dC. However, unlike experiments exploring p16, Zebularine was only 
able to slightly increase gene expression in T24 cells compared to 253J cells, which 
displayed a large increase in expression. The difference in gene activation between these 
two cell lines could be the result of differing degrees of DNA methylation. At baseline, 
253J cells were found to have slight SH3GL2 mRNA expression, while T24 had none. 
Thus, Zebularine was unable to decrease methylation to a significant degree in order to 
trigger the increase in mRNA level in T24 cells. 5-Aza-dC, which is a much stronger 
demethylating agent than Zebularine, as evidenced by the lower dose required to trigger 
gene activation, was able to overcome this barrier. The final drug explored was RG-108. 
Unlike Zebularine and 5-Aza-dC, RG-108 is a DNMT inhibitor that binds directly to the 
active site of the enzyme (Heerboth et al., 2014). It therefore appears that RG-108 is a much 
less toxic compound to cells compared to the cytidine analogs, 5-Aza-dC and Zebularine. 
Also, a much higher concentration (500µM) was used with little observed cytotoxicity to 
cells. However, unlike Zebularine and 5-Aza-dC, RG-108 was unable to cause gene 
reactivation. RG-108 has been used in previous studies to explore its ability to reactivate a 
tumor suppressor gene silenced through DNA methylation and was unable to cause 
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significant demethylation and reactivation compared to 5-Aza-dC (Stresemann et al., 
2006). Previous studies have used RG-108 at higher doses than those used during this 
experiment (Sun et al., 2016), and this may be an interesting avenue to explore in future 
studies. Interestingly, RG-108 at 500µM was able to increase SH3GL2 protein levels in 
J82 cells (Figure 9). J82 cells contain approximately 70% DNA hypermethylation of the 
promoter compared to approximately 100% in both T24 and 253J cells. The decrease in 
baseline DNA methylation of J82 cells compared to T24 and 253J could explain how RG-
108 was able to increase protein expression compared to no increase in RNA expression in 
253J and T24 BC cells. Overall, each drug utilizes different mechanisms with different 
stability and toxicity and a possible combination approach between RG-108 and the 
cytidine analogs could be used to achieve promoter demethylation. 
 SH3GL2 promotes EGFR internalization after activation and its loss is associated 
with increased cell proliferation both in-vitro and in-vivo (Majumdar et al., 2013). 
Conversely, SH3GL2 re-expression resulted in reduced tumor cell proliferation. Similar to 
the data presented above, which forced re-expression of SH3GL2 in a BC model, re-
expression of SH3GL2 in a lung cancer model resulted in a significant decrease in cell 
growth, invasion and colony formation (Dasgupta et al., 2013). As a result, the targeting of 
SH3GL2 by the demethylating agents described above could be used as a cancer therapy 
to slow cancer proliferation. Previously, demethylating agents have only been approved to 
treat non-solid tumors such as leukemia and myelodysplastic syndrome (Li et al., 2016). 
These agents need to be given intravenously and can often lead to many off-target effects. 
However, because the bladder is easily accessible relative to many other organs in the body, 
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the use of these agents injected directly into the bladder could possibly help slow BC 
progression. Previous studies have used Zebularine to reactivate p16 expression in human 
bladder tumor cells in-vivo and have found it to be stable over long periods of time (Cheng 
et al., 2003). In-vivo models of reactivation of SH3GL2 are needed to assess the benefits 
of demethylating agents on tumor growth and behaviour.  
Further research is also needed to assess the effect of demethylation and subsequent 
reactivation of SH3GL2 on regulation of RTK activation in BC cell lines. Normal SH3GL2 
function would allow proper receptor internalization and inactivation after EGF binding. 
However, the impact of SH3GL2 re-expression on restoration of this function remains 
unknown. In addition, the loss of SH3GL2 may identify tumors in which the EGFR and/or 
c-MET remain active due to the lack of internalization, and therefore may be more sensitive 
to treatment with EGFR or c-MET tyrosine kinase inhibitors (TKI). The loss of SH3GL2 
is an early event in BC pathogenesis (Majumdar et al., 2013). As a result, the level of 
methylation of SH3GL2 and by inference the extent of SH3GL2 gene and protein 
expression could serve as a novel biomarker to identify patients who need more aggressive 
treatment early in the disease. Further study is needed to correlate the level of methylation 
of the SH3GL2 promoter in BC specimens from patients and clinical outomes, as well as 
the ability of SH3GL2 expression status to predict sensitivity to TKIs (EGFR, c-met 
inhibitors). 
 Beyond the possible impact of SH3GL2 status on response to TKI therapy, its loss 
has been found to impact patients’ response to chemotherapy in ovarian cancer (Osterberg 
et al., 2009). This study found that the loss of SH3GL2 or CIN85 was associated with 
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chemotherapy-resistance in ovarian cancer. In chemotherapy-resistant tumors, 70% had 
losses in either SH3GL2 or CIN85 (Osterberg et al., 2009). This function of SH3GL2 
suggests it can be involved in resistance to drugs in tumors. This drug resistance could 
possibly be extended beyond ovarian cancer and could be used to explain why certain 
patients do not respond to a given therapeutic intervention. Another possible hypothesis is 
that the reactivation of SH3GL2 could be used as an initial therapy to allow cancer cells to 
be more responsive to specific therapies. Further study is needed to assess the impact of 
SH3GL2 loss in drug resistance.  
Study limitations 
 There were several limitations in this study. While the demethylating agents are 
effective at demethylating promoter regions, the specificity of these agents was lacking. 
The addition of these drugs will likely cause systemic demethylation in many promoter 
regions and could result in reactivation of many silenced genes. A variety of other 
mechanisms have been found that could be used to directly activate genes silenced by 
methylation. Small non-coding double stranded RNA (dsRNA) have recently been found 
that can localize to specific promoter regions and produce an increase in gene expression 
(Li et al., 2006). These dsRNA are sequence-specific and will bind complementary to 
specific promoter regions and thus could be used as an alternative to upregulate SH3GL2 
rather than the global demethylation effect caused by the demethylating drugs (Li et al., 
2006).  
 Another limitation of this study was the variability in results achieved when adding 
these demethylating agents. Certain experiments did not lead to detectable gene 
	
 38	
reactivation possibly due to the effect of stability of these drugs in solution or insufficient 
time needed in order to reactivate SH3GL2. More research is needed in order to identify a 
specific protocol that allows sufficient time for the agents to work while also maintaining 
stability in solution. In addition, all of the drugs were dissolved in DMSO. DMSO as a 
vehicle has been shown to affect the epigenetic profile and cause hypermethylation in 
several gene loci (Iwatani et al., 2006). As a result, the vehicle could be acting to counteract 
the activity of the demethylating agent which might explain the variable results as well as 
the changes in baseline SH3GL2 level.  
 In conclusion, the data presented here outlines three different demethylating agents 
that could be used to reactivate SH3GL2 in BC tumor cells that could be used to change 
tumor cell behavior. Interestingly, the SH3GL2 promoter was not methylated in all BC cell 
lines, suggesting alternative mechanisms beyond epigenetic modifications might lead to 
the lack of SH3GL2 expression. Overall, these findings suggest a mechanism for SH3GL2 
reactivation in an in-vitro model. However, further exploration is needed to assess if the 
results could translate to an in-vivo model. In addition, further research is needed to explore 
what effect the reactivation of SH3GL2 by demethylation agents has on BC tumor cell 
behavior, response to TKI treatment and whether this method could be utilized as a new 
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